It is estimated that treating diagnosed depression costs £420 million annually in England and Wales.
This economic study analyses treatment of major depression with nefazodone v. imipramine.
The study updates a previously published model using data obtained from the continuation phase of a double-blind one-year placebo-controlled comparison of nefazodone with imipramine.
Annual costs for nefazodone are lower than those for imipramine, £218 compared to £254 ; the cost per successfully treated patient is also lower for nefazodone than for imipramine, £242 v. £323.
Varying the resources included in the treatment patterns still results in lower costs for nefazodone treatment.
Based on clinical trial data for patients completing six to eight weeks of depression treatment and followed for at least one year, the model shows that the annual costs of nefazodone are lower than those for the less expensive imipramine.
Mots-clés Pascal : Imipramine, Néfazodone, Etude comparative, Analyse coût, Economie santé, Chimiothérapie, Traitement, Composé tricyclique, Antagoniste, Récepteur sérotoninergique 5-HT2, Inhibiteur recapture, Sérotonine, Homme, Etat dépressif, Trouble humeur
Mots-clés Pascal anglais : Comparative study, Cost analysis, Health economy, Chemotherapy, Treatment, Tricyclic compound, Antagonist, 5-HT2 receptor, Reuptake inhibitor, Serotonin, Human, Depression, Mood disorder
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0328330
Code Inist : 002B02B02. Création : 10/04/1997.